ClinicalTrials.gg
CompletedNCT00638716DM200-101Updated Jun 2, 2017Results posted

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy

A Phase 2 interventional study of CJC-1134-PC and Placebo in Type 2 Diabetes Mellitus, sponsored by ConjuChem. Completed at 1 site in Canada. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2017-06-02.

Sponsored by ConjuChem · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 756 studies in Diabetes Mellitus, Type 2 with a site in Canada — 81 open to participants now, 112 under way, 25 of them phase 3. Diabetes Mellitus, Type 2 · Canada.

Enrollment
413th of 673
122 · median 227
Started
2008
with 45 others
Phase 2
107 of 756
4 open now
Registered
113th of 756
by date

Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, this one is the 413th largest by enrollment of the 673 interventional ones that give a count, is one of 46 that started in 2008, is one of 107 in phase 2, and was the 113th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

81 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Canada are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 756 studies in Diabetes Mellitus, Type 2 with a site in Canada, or all of them as a file.
02

Study summary

This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study.

The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes mellitus who are currently on metformin monotherapy.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus, incretins, GLP-1, HbA1c, metformin
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • : 27 to 45 kg/m2
  • Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator
  • Stable life-style, i.e. diet \& physical activity, as determined by the Investigator
  • Stable metformin daily dose ≥1000 mg for at least 3 months
  • Glycosylated () at screening ≥ 7.1% and ≤ 11%
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    1

    12 weekly doses of 1.5 mg CJC-1134-PC

    Drug: CJC-1134-PC

  • Experimental
    2

    4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC

    Drug: CJC-1134-PC

  • Placebo comparator
    3

    12 weekly doses of placebo

    Drug: Placebo

Interventions

  • 1.5 or 2.0 mg CJC-1134-PC

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Reduction of HbA1c From Baseline

    Change from Baseline

    Time frame: Screening and Day 85

Secondary outcomes

  1. Reduction in FPG From Baseline

    Change from Baseline

    Time frame: Screening and Day 85

  2. Reduction in Fasting Body Weight From Baseline

    Change from Baseline

    Time frame: Screening and Day 85

07

Results

Posted Jun 2, 2017

Participant flow

Participant flow — Overall Study
Milestone1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlacebo
Started505258
Completed433746
Not completed71512

Outcome measures

PrimaryReduction of HbA1c From Baseline

Change from Baseline

Time frame:
Screening and Day 85
Reported as:
Mean · Percent (%)
Reduction of HbA1c From Baseline
Percent (%)1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlacebo
Reduction of HbA1c From Baseline-0.85 ± 0.883-0.80 ± 0.827-0.46 ± 0.744
SecondaryReduction in FPG From Baseline

Change from Baseline

Time frame:
Screening and Day 85
Reported as:
Mean · mg/dL
Reduction in FPG From Baseline
mg/dL1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlacebo
Reduction in FPG From Baseline-13.48 ± 34.579-18.76 ± 36.736-10.06 ± 34.137
SecondaryReduction in Fasting Body Weight From Baseline

Change from Baseline

Time frame:
Screening and Day 85
Reported as:
Mean · kg
Reduction in Fasting Body Weight From Baseline
kg1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlacebo
Reduction in Fasting Body Weight From Baseline-1.98 ± 2.438-1.25 ± 2.106-1.58 ± 2.374

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg CJC-1134-PC0/49 (0%)0/49 (0%)36/49 (73.5%)
1.5 or 2.0 mg CJC-1134-PC0/49 (0%)0/49 (0%)30/49 (61.2%)
Placebo0/57 (0%)0/57 (0%)34/57 (59.6%)
Most frequent other events
Showing 10 of 12
Most frequent other events
Event1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlacebo
NauseaGastrointestinal disorders11/4915/499/57
HeadacheNervous system disorders5/492/499/57
DiarrheaGastrointestinal disorders6/496/493/57
VomitingGastrointestinal disorders6/492/492/57
DizzinessNervous system disorders2/492/494/57
Urinary tract infectionInfections and infestations3/491/492/57
AnorexiaMetabolism and nutrition disorders2/493/490/57
Back painMusculoskeletal and connective tissue disorders0/493/491/57
Injection site bruisingGeneral disorders0/490/493/57
NasopharyngitisInfections and infestations2/492/493/57

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlaceboTotal
Mean55.2 ± 10.4655.1 ± 12.2457.2 ± 13.0555.9 ± 11.99
Sex: Female, Male
Sex: Female, Male(Participants)1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlaceboTotal
Female21283079
Male28212776
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlaceboTotal
Hispanic or Latino48517
Not Hispanic or Latino454152138
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 mg CJC-1134-PC1.5 or 2.0 mg CJC-1134-PCPlaceboTotal
American Indian or Alaska Native0112
Asian45918
Native Hawaiian or Other Pacific Islander0000
Black or African American99725
White343336103
More than one race0000
Unknown or Not Reported2147
08

Study locations

1 site
  • ConjuChem Biotechnologies Inc.
    Montreal, Quebec H2X 3Y8, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 8 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2008
First posted
Mar 19, 2008
Start
Feb 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Jun 2, 2017
Last update
Jun 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00638716
Lead sponsor
ConjuChem
Responsible party
Sponsor
First posted
Mar 19, 2008
Start date
Feb 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Jun 2, 2017
Last update
Jun 2, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albenatide

Start the discussion